pdf   xlsx method abbreviations

mNSCLC - L2 - all population, ... , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.93 [0.81, 1.07]< 164%6 studies (6/-)83.4 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 1.00 [0.81, 1.22]< 187%6 studies (6/-)51.7 %some concernnot evaluable moderateimportant-
objective responses (ORR) 0.93 [0.61, 1.42]> 172%6 studies (6/-)36.1 %some concernnot evaluable moderatenon important-

safety endpoints 00

TRAE (any grade) 0.56 [0.34, 0.94]< 10%1 study (1/-)98.7 %NAnot evaluable non important-
TRAE (grade 3-4) 0.60 [0.44, 0.81]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 0.27 [0.05, 1.32]< 10%1 study (1/-)94.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons